Surrozen

Surrozen is a clinical-stage biotech leveraging its proprietary antibody-engineering platform to create Wnt-modulating therapies, initially targeting major ophthalmic indications like diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The company's approach aims to address underlying disease pathology by restoring tissue integrity and function, positioning its candidates as potential best-in-class treatments. With a seasoned leadership team and backing from prominent life science investors, Surrozen is advancing a focused pipeline built on foundational discoveries in Wnt biology.

Proprietary antibody-engineering platform to discover multifunctional antibodies that precisely modulate the Wnt signaling pathway and other key drivers of disease pathology.

Surrozen competes in the crowded retinal disease space dominated by anti-VEGF therapies (e.g., Lucentis, Eylea, Vabysmo) and their biosimilars. It also faces competition from companies developing longer-acting anti-VEGF agents, gene therapies, and alternative pathway inhibitors. Its differentiation hinges on its unique Wnt mechanism.